Unity Biotechnology, Inc.

OTCPK:UNBX Stock Report

Market Cap: US$965.6k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Unity Biotechnology Future Growth

Future criteria checks 0/6

Unity Biotechnology is forecast to grow revenue at 76.6% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate76.6%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Oct 2025

Recent future growth updates

Recent updates

Analysis Article • Nov 05

Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 12

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 05

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Nov 18

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 19

UNITY Biotechnology falls 7% on reverse stock split

Unity Biotechnology (NASDAQ:UBX) announced on Wednesday a 1-for-10 reverse stock split of its common stock, sending its shares down 7.6% in premarket trading. The reverse stock split will become effective at 5:00 PM on Wednesday. The company said it was going ahead with the reverse stock split to be in compliance with the minimum required closing bid price for continued listing on the Nasdaq Global Select Market. The reverse stock split was approved by UNITY’s stockholders at a special meeting of stockholders held on October 18.
Seeking Alpha • Aug 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Unity Biotechnology (NASDAQ:UBX) has halved a stock sales agreement to $25M from $50M, according to a Friday SEC filing. The sales agreement is through Cowen. Unity noted that it already sold $8.9M worth of shares under the agreement. On Thursday, the company priced shares of another offering of its common stock and accompanying warrants at a combined public offering price of $0.70/share and accompanying warrant. The gross proceeds are expected to be $45M.
Seeking Alpha • Aug 12

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Unity Biotechnology press release (NASDAQ:UBX): Q2 GAAP EPS of -$0.19 beats by $0.10. Revenue of $0.24M. Cash, cash equivalents and marketable securities totaled $64.5 million as of June 30, 2022, compared with $79.2 million as of March 31, 2022.  UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations through the first quarter of 2023. Shares +96% PM.
Seeking Alpha • Jul 26

A Look At Unity's UBX1325 Phase 1 Results

I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases. UBX1325 had posted strong preclinical results that suggested senescent cells might actually be causally involved in various retinal disease pathologies. Unity recently posted results from its first-in-human Phase 1 trial of UBX1325 that I thought merited a closer look.
Analysis Article • Dec 22

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Some Unity Biotechnology, Inc. ( NASDAQ:UBX ) shareholders may be a little concerned to see that the Co-Founder...

Earnings and Revenue Growth Forecasts

OTCPK:UNBX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/AN/AN/AN/A1
12/31/2026N/AN/AN/AN/A1
12/31/2025N/AN/AN/AN/A1
3/31/2025N/A-28-22-22N/A
12/31/2024N/A-26-21-21N/A
9/30/2024N/A-22-23-23N/A
6/30/2024N/A-30-24-24N/A
3/31/2024N/A-40-31-31N/A
12/31/2023N/A-40-37-37N/A
9/30/2023N/A-34-41-41N/A
6/30/2023N/A-33-45-45N/A
3/31/20230-31-49-49N/A
12/31/20220-44-53-52N/A
9/30/20225-56-46-46N/A
6/30/20225-59-47-46N/A
3/31/20225-64-45-45N/A
12/31/20215-61-45-45N/A
9/30/2021N/A-70-57-57N/A
6/30/2021N/A-81-63-62N/A
3/31/2021N/A-82-69-68N/A
12/31/2020N/A-94-79-78N/A
9/30/2020N/A-92-78-77N/A
6/30/2020N/A-86-78-77N/A
3/31/2020N/A-91-78-77N/A
12/31/2019N/A-82-74-72N/A
9/30/2019N/A-86-71-70N/A
6/30/2019N/A-83-68-67N/A
3/31/2019N/A-79-67-65N/A
12/31/2018N/A-76N/A-57N/A
9/30/20181-67N/A-55N/A
6/30/20181-60N/A-51N/A
3/31/20181-52N/A-42N/A
12/31/20171-45N/A-38N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if UNBX's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if UNBX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if UNBX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: UNBX is forecast to have no revenue next year.

High Growth Revenue: UNBX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if UNBX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 23:35
End of Day Share Price 2025/10/01 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Unity Biotechnology, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Matthew HarrisonMorgan Stanley
Dylan DupuisRoth Capital Partners